Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424689 | 0.88 | CCR2 (0.57) | CCR2MAOBMAOA | |
| SCHEMBL5757482 | 0.88 | CCR2 (0.57) | CCR2MAOBMAOA | |
| SCHEMBL2990164 | 0.88 | CCR2 (0.57) | CCR2MAOBMAOA | |
| SCHEMBL4417528 | 0.81 | ALDH1A1 (0.47) | CCR2MAOBKDM1AKMT2AL3MBTL1 | |
| SCHEMBL4419851 | 0.81 | CCR2 (0.54) | CCR2MAOBKDM1AKMT2AL3MBTL1 | |
| SCHEMBL5543212 | 0.77 | MAOB (0.52) | MAOBKDM1AMAOAKMT2AL3MBTL1 | |
| SCHEMBL5548715 | 0.77 | MAOB (0.52) | MAOBKDM1AMAOAKMT2AL3MBTL1 | |
| SCHEMBL5548711 | 0.77 | MAOB (0.52) | MAOBKDM1AMAOAKMT2AL3MBTL1 | |
| SCHEMBL5756396 | 0.74 | CCR2 (0.59) | CCR2MAOBMAOA | |
| SCHEMBL2991013 | 0.74 | CCR2 (0.59) | CCR2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776884-B2 | Cyclic derivatives as modulators of chemokine receptors activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| US-7087604-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CHERNEY ROBERT J | 2006-06-22 | — | — | US | disclosed |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135503-A1 | Cyclic derivatives as modulators of chemokine receptors activity | CCL11, CCR1, CCL2 | CCR2 10/4885MAOB 3499/4885KDM1A 4507/4885 |
| US-20030216434-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCR1, CCL11, CXCR1 | CCR2 10/4885MAOB 3374/4885KDM1A 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.